MSLN overexpression
|
Ovarian Cancer
|
MSLN overexpression
|
Ovarian Cancer
|
TC-210 Sensitive: C3 – Early Trials
|
TC-210 Sensitive: C3 – Early Trials
|
MSLN overexpression
|
Malignant Pleural Mesothelioma
|
MSLN overexpression
|
Malignant Pleural Mesothelioma
|
TC-210 Sensitive: C3 – Early Trials
|
TC-210 Sensitive: C3 – Early Trials
|
MSLN overexpression
|
NSCLC
|
MSLN overexpression
|
NSCLC
|
afatinib Resistant: D – Preclinical
|
afatinib Resistant: D – Preclinical
|
MSLN overexpression
|
AML
|
MSLN overexpression
|
AML
|
BAY 94-9343 Sensitive: D – Preclinical
|
BAY 94-9343 Sensitive: D – Preclinical
|